NTLA

Intellia Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 6/10
  • Momentum↑ 8/10
Intellia Therapeutics sales and earnings growth
NTLA Growth
Good
  • Revenue Y/Y↑ 33.52%
  • EPS Y/Y↑ 21.69%
  • FCF Y/Y↓ -13.65%
Intellia Therapeutics gross and profit margin trends
NTLA Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↓ -774.90%
  • ROIC↓ -51.60%
Intellia Therapeutics net debt vs free cash flow
NTLA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Intellia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗